Since founding HighTide in 2011, Dr. Liping Liu has been primarily responsible for fundraising, overall management of the business strategy, corporate development, and research and development of the Company. Dr. Liu has over 20 years of experience in the R&D of innovative drugs, and has accumulated wealthy knowledge and experiences in therapeutic development for metabolic and digestive disease. Prior to founding HighTide, she served management positions in several U.S. biotech companies, including Associate Director of Antigen Discovery of CTL ImmunoTherapies Corporation, senior R&D manager of MannKind Corporation, head of translational medicine and proteomics department of American Type Culture Collection, Head of Global R&D of Stealth Peptide Inc., and chairwoman of the board of directors and chief scientific officer of ABLE BioGroup LLC., respectively. She is a co-inventor of an FDA approved antidiabetic drug, and has contributed to over 10 IND submissions as well as 100+ international patent applications and issuance. 

Dr. Liu received her doctoral degree in Polymer Chemistry and Physics from Nankai University, completed post-doctoral training at the University of Toronto, and obtained an MBA degree from Johns Hopkins University Carey Business School.